Eisai Co., Ltd.: all 644 studies

Page 5 of 7. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy SubjectsCompletedNCT02809768Phase 1
• Eribulin [Halaven] Use For the Treatment of Advanced Breast CancerCompletedNCT02790320
• Extended Treatment in Metastatic Breast Cancer With EribulinCompletedNCT02769364
• Post-Marketing Surveillance of Lenvima in Korean PatientsCompletedNCT02764554
• Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With EpilepsyCompletedNCT02736162
• A Study of Fycompa (Perampanel) in Korean ParticipantsCompletedNCT02722590
• Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly SubjectsCompletedNCT02583451Phase 1
• Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy VolunteersCompletedNCT02533102Phase 1
• Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia PatientsCompletedNCT02455271
• Investigation of the Safety and Efficacy of Eszopiclone in Insomnia PatientsCompletedNCT02452684
• Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).CompletedNCT02448784
• Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational RegistryCompletedNCT02443428
• Halaven Post-Marketing Surveillance (PMS)CompletedNCT02441764
• Symbenda Post-Marketing Surveillance (PMS)CompletedNCT02434484
• Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)CompletedNCT02430714
• Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose AspirinCompletedNCT02423187
• A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)CompletedNCT02421042Phase 1
• Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult SubjectsCompletedNCT02415790Phase 1
• A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of AgeCompletedNCT02398669Phase 1
• Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.CompletedNCT02371174
• A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)CompletedNCT02345213Phase 4
• An Extended Access Program (EAP) for PerampanelNo longer availableNCT02307578
• Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)CompletedNCT02300532
• Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade GliomaCompletedNCT02300506
• A Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese SubjectsCompletedNCT02289599Phase 1
• A Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy SubjectsCompletedNCT02279485Phase 1
• Post-marketing Surveillance of DC Bead in Patients With Hepatocellular CarcinomaCompletedNCT02269995
• Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male SubjectsCompletedNCT02268838Phase 1
• A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS)CompletedNCT02262975
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's DiseaseWithdrawnNCT02249078Phase 1
• Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and TaxanesCompletedNCT02225470Phase 3
• A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly MalesCompletedNCT02225288Phase 1
• A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy SubjectsCompletedNCT02222324Phase 1
• To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset SeizuresWithdrawnNCT02220972Phase 4
• An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid CancerApproved for marketingNCT02211222
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White SubjectsCompletedNCT02207790Phase 1
• A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy VolunteersCompletedNCT02199392Phase 1
• A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy SubjectsCompletedNCT02199379Phase 1
• A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy VolunteersCompletedNCT02198170Phase 1
• A Study of APD356 (Lorcaserin) in Healthy Japanese Adult SubjectsCompletedNCT02192515Phase 1
• Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition in Patients With Change From Botulinum Toxin Type ACompletedNCT02175719
• Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical DystoniaCompletedNCT02175693
• Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut SyndromeCompletedNCT02175173
• Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical PracticeCompletedNCT02162264
• Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's DiseaseCompletedNCT02162251
• A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease PatientsCompletedNCT02158910
• A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male SubjectsCompletedNCT02146261Phase 1
• An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male SubjectsCompletedNCT02116907Phase 1
• A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's DiseaseCompletedNCT02094729Phase 1
• A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.CompletedNCT02094053Phase 2
• A Study to Determine the Effect of a High-Fat Meal on the Rate and Extent of E2006 Absorption in Healthy SubjectsCompletedNCT02089412Phase 1
• A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or BupropionCompletedNCT02085967Phase 1
• A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or DonepezilCompletedNCT02055703Phase 1
• An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male SubjectsCompletedNCT02046213Phase 1
• A Phase 1 Comparative Study of E2022 Current and New Patch FormulationsCompletedNCT02042729Phase 1
• A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White SubjectsCompletedNCT02039089Phase 1
• A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White SubjectsCompletedNCT02039076Phase 1
• A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 YearsCompletedNCT02033902
• Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of AgeCompletedNCT02022956Phase 1
• A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy SubjectsCompletedNCT02020486Phase 1
• European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)CompletedNCT01991041
• An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male SubjectsCompletedNCT01975636Phase 1
• An Extended Access Program for PerampanelNo longer availableNCT01871233
• Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid ArthritisCompletedNCT01850966
• A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals in Japanese Healthy Elderly MalesCompletedNCT01843556Phase 1
• A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)CompletedNCT01830868
• A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)CompletedNCT01830400
• A Single-dose Study in Healthy Japanese Male Adults to Evaluate Pharmacokinetics and Pharmacodynamics of E5501 5 mg Tablet (Study E5501-J081-015)CompletedNCT01774773Phase 1
• A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)CompletedNCT01773434Phase 1
• A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat MealCompletedNCT01759394Phase 1
• MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
• A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)CompletedNCT01731275Phase 1
• An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on AbsorptionCompletedNCT01716897Phase 1
• Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum SymptomCompletedNCT01715493Phase 4
• Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule FormulationsCompletedNCT01673880Phase 1
• 2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly SubjectsCompletedNCT01673451Phase 1
• Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled StudyCompletedNCT01645800Phase 4
• Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic DrugCompletedNCT01630057Phase 4
• An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid TumorsCompletedNCT01618136Phase 1/2
• Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III MelanomaTerminatedNCT01605162Phase 2
• Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)CompletedNCT01600859Phase 1
• A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501CompletedNCT01549054Phase 1
• Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's DiseaseCompletedNCT01539031Phase 3
• A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With PerampanelCompletedNCT01531920Phase 1
• A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc IntervalCompletedNCT01525394Phase 1
• A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing CancersCompletedNCT01521325Phase 1
• Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy SubjectsCompletedNCT01511783Phase 1
• A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult MalesCompletedNCT01506752Phase 1
• A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult MalesCompletedNCT01506739Phase 1
• Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)CompletedNCT01463891
• E2022 Patch Formulation Multiple Dose StudyCompletedNCT01450839Phase 1
• Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.CompletedNCT01437384Phase 1
• Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)No longer availableNCT01432483
• A Phase I Study of E7050 in Subjects With Solid TumorsCompletedNCT01428141Phase 1
• An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal FunctionCompletedNCT01418677Phase 1
• A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's DiseaseCompletedNCT01404169Phase 3
• Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy SubjectsCompletedNCT01396590Phase 1
• Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy SubjectsCompletedNCT01396577Phase 1
• Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese SubjectsCompletedNCT01390714Phase 1
• Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis SubjectsCompletedNCT01357759Phase 1

← Eisai Co., Ltd. overview and focus areas